Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 169 | 0.85 |
| pathways Reactome | 5 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 6828
Sealed predictions
- NTHL1 in dopamine neurons, braak+0.21 (p 0.586) → -0.35 (p 0.354)receipt 6834
Swarm cases
receipt 6834: NTHL1 in dopamine neurons, braak
- power
- full sample -0.01 (p 0.976, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.04 (p 0.861, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.29 (p 0.235, n 18). could be the mix.
- skeptic
- leave-one-out range -0.13 to +0.12, sign flips 6; without severely affected donors -0.01 (p 0.976, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.63 (p 0.0055, n 18) vs -0.01 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NTHL1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up NTHL1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.25 p 0.374 (needs p < 3.0e-4)
Receipts
loading the receipts